Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis

N Engl J Med. 2019 Mar 7;380(10):981-983. doi: 10.1056/NEJMc1811317.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intravenous
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Interleukins / genetics
  • Interleukins / metabolism
  • Male
  • Mutation
  • Psoriasis / drug therapy*
  • Receptors, Interleukin / antagonists & inhibitors*
  • Severity of Illness Index

Substances

  • Antibodies, Monoclonal, Humanized
  • IL36RN protein, human
  • Interleukins
  • Receptors, Interleukin
  • interleukin-36 receptor, human
  • spesolimab